<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176762">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794313</url>
  </required_header>
  <id_info>
    <org_study_id>e4717</org_study_id>
    <nct_id>NCT00794313</nct_id>
  </id_info>
  <brief_title>Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease</brief_title>
  <official_title>Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and
      uncontrolled movements called dyskinesias. A drug called amantadine can reduce these
      movements. To date, there are no objective measures of these movements. The purpose of this
      study is to measure the reduction of the movements by amantadine and/or topiramate using an
      objective measure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted
      movements (dyskinesias) caused by the gold standard treatment, Levodopa. The severity of
      these movements can range from subtle to extremely debilitating and may or may not interfere
      with normal activities such as putting on a coat or brushing ones teeth. Currently, one of
      the very few treatments for these unwanted and involuntary movements is Amantadine. New
      options to treat dyskinesia would be clinically very valuable. In a previous study, we
      developed an objective measuring device to quantify dyskinesia.

      All PD participants will receive all three of the drug treatment intervention (placebo,
      Amantadine 300 mg, Amantadine 300 mg plus Topiramate 150 mg). After 2 weeks of one drug
      treatment, the participants will complete an overnight visit at the OCTRI Inpatient unit.
      During the next day, participants will complete a mental task while standing on a force
      plate for one minute every half hour until the end of the study. A levodopa IV infusion will
      occur from 0900 to 1100. The subjects will be split into 'high' and 'low' dose groups. Those
      who take &lt;50 mg/hour of oral levodopa or levodopa equivalents will be considered 'low' dose
      subjects and will receive 1 mg/kg/hr of IV Levodopa during the study visits (1, 2, and 3).
      Those who administer &gt; 50 mg/hr of oral levodopa to themselves normally will be considered
      'high' dose subjects and will received 1.5 mg/kg/hr levodopa. Both groups will receive the
      infusion for two hours from 0900 - 1100. The study drug will be taken orally at 0800.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding Ended
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forceplate Measurement of Dyskinesia</measure>
    <time_frame>up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inertial Sensor Signal</measure>
    <time_frame>2 weeks, 5 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amantadine plus Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine 300 mg</intervention_name>
    <description>Amantadine, 300 mg, capsule, three times a day, two weeks</description>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_label>Amantadine plus Topiramate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week</description>
    <arm_group_label>Amantadine plus Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>sugar pill, capsule, three times a day, 2 weeks</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's Disease

          -  At least 21 years of age

          -  Must be taking Oral levodopa

          -  Must have dyskinesias by history or previous clinical observation

        Exclusion Criteria:

          -  Significant cognitive impairment as measured by the Montreal Cognitive Assessment
             (MOCA) score of &lt; 25

          -  Subjects with unstable medical or psychiatric conditions (including hallucinations)

          -  Use of dopamine receptor blocking medications (e.g., neuroleptics, certain
             antiemetics, tetrabenazine)

          -  History of unstable medical conditions (ie active cardiovascular disease, recent
             unwellness or surgery etc.)

          -  Use of anticoagulants

          -  Current substance abuse

          -  Previous adverse event on amantadine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health &amp; Science University, Portland VA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John G Nutt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health &amp; Science Unversity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000 Mar-Apr;23(2):82-5.</citation>
    <PMID>10803797</PMID>
  </reference>
  <reference>
    <citation>Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998 May;50(5):1323-6.</citation>
    <PMID>9595981</PMID>
  </reference>
  <reference>
    <citation>Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001 May;16(3):515-20.</citation>
    <PMID>11391748</PMID>
  </reference>
  <reference>
    <citation>Hagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord. 1999 May;14(3):448-55.</citation>
    <PMID>10348468</PMID>
  </reference>
  <reference>
    <citation>da Silva-JÃºnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord. 2005 Nov;11(7):449-52. Epub 2005 Sep 9.</citation>
    <PMID>16154788</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 11, 2012</lastchanged_date>
  <firstreceived_date>November 19, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Kathryn Chung, MD</name_title>
    <organization>Oregon Health &amp; Science University</organization>
  </responsible_party>
  <keyword>Parkinsons disease</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>amantadine</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
